Market Research Report On Paclitaxel Injection

1
Global Paclitaxel Injection Market 
Opportunities and Forecasts, 2013 - 2020
2
REPORT DESCRIPTION
The report provides market analysis, information
and insights into Paclitaxel Injection
Market  Paclitaxel belongs to the group of
medications known as antineoplastics and is used
in the treatment of cancers. It works by
inhibiting the growth of cancer cells and is used
in the treatment of various cancers such as
breast cancer, ovarian cancer, non small cell
lung cancer, etc. According to the WHO, cancer
was the leading cause of death worldwide,
accounting for the death of 8.2 million people in
2012. The major drivers for this market are the
rising incidence of cancer globally and the
improved efficacy of paclitaxel injections.
However, adverse drug reactions associated with
the drug as well as the emergence of targeted
treatment, personalized medicine and novel
anti-cancer drugs would be a challenge to the
growth of this market. The opportunities for this
market are its potential to be used for treatment
for various types of cancers. View Sample
Report_at_ http//www.bigmarketresearch.com/paclitaxe
l-injection-market
3
KEY MARKET BENEFITS

• Market segmentation by use of the product would
  help in identification of future applications
• Porters five force model helps in making
  strategic business decisions for business
  development
• In-depth geographic Analysis would aid in
  identifying regions where demand for this product
  would increase
• In-depth analysis of drivers and opportunities
  would help in understanding the future potential
  of this market
•  

4
KEY MARKET SEGMENTS
Paclitaxel Injection Market by use in treatment
of various cancers   Paclitaxel Injection is used
in the treatment of Breast cancer, Ovarian
cancer, Non small cell lung cancer, AIDS related
Kaposi's sarcoma, Cervical Cancer, Esophageal
cancer, Prostate cancer , Stomach cancer,
Testicular cancer, Lung cancer, Pancreatic
cancer, and Others. According to the WHO, stomach
cancer accounted for 723,000 deaths and breast
cancer accounted for 521,000 deaths respectively
in the year 2012 alone. Paclitaxel is used for
the treatment of both these cancers and the
rising incidences of cancer would result in
increased use of this drug for treatment.   Paclit
axel Injection Market by Geography   Paclitaxel
Injection Market is segmented geographically into
North America, Europe, Asia Pacific and RoW.
Currently the market is dominated by North
America due to the high incidence of Cancer
patients in this region. However, Europe and Asia
Pacific are emerging markets due to rising
incidences of cancer.
5
MARKET OVERVIEW
Competitive analysis   The companies in this
market are Abraxis Bio Science Inc., Celgene,
Abbott Laboratories, Fresenius Kabi Oncology Ltd,
Onco therapies Ltd, Novasep, Sagent
Pharmaceuticals and others. The European
Commission approved ABRAXANE to be taken in
combination with Gentamicin for the treatment of
metastatic pancreatic cancer in January 2014.
ABRAXANE was developed by Celgene International
Sàrl, a subsidiary of Celgene Corporation.   High
Level Analysis   Porters five force model
analyzes the bargaining power of the suppliers
and buyers as well as the threat of new entrants.
The threat of substitutes in this market is high,
with extensive research and development being
carried out in anti-cancer drugs. SWOT analysis
helps in making strategic decisions for
development and expansion. The key drivers,
restraints and opportunities are analyzed to help
in better understanding the growth of this
market.  
6
SUMMARY
Paclitaxel is used for the treatment of both
these cancers and the rising incidences of cancer
would result in increased use of this drug for
treatment. The companies in this market are
Abraxis Bio Science Inc., Celgene, Abbott
Laboratories, Fresenius Kabi Oncology Ltd, Onco
therapies Ltd, Novasep, Sagent Pharmaceuticals
and others. The European Commission approved
ABRAXANE to be taken in combination with
Gentamicin for the treatment of metastatic
pancreatic cancer in January 2014. ABRAXANE was
developed by Celgene International Sàrl, a
subsidiary of Celgene Corporation.
Enquiry For Report_at_ http//www.bigmarketresearch.c
om/report-enquiry/22831
7
FOR MORE DETAILS
Visit us at
www.bigmarketresearch.com
Stay With Us
TELEPHONE [phone] EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States